Monoclonal antibody-targeted polymeric nanoparticles for cancer therapy - future prospects

Although combination therapy for cancer utilising monoclonal antibodies in conjunction with chemotherapeutic drugs has resulted in increases in 5 year survivals, there nevertheless remains significant morbidity and mortality associated with systemic delivery of cytotoxic drugs. The advent of living...

Full description

Saved in:
Bibliographic Details
Published inJournal of chemical technology and biotechnology (1986) Vol. 90; no. 7; pp. 1169 - 1176
Main Authors Goodall, Stephen, Jones, Martina L., Mahler, Stephen
Format Journal Article
LanguageEnglish
Published Chichester, UK John Wiley & Sons, Ltd 01.07.2015
Wiley Subscription Services, Inc
Subjects
antibody
Cancer
drug delivery
Drug delivery systems
Drugs
fragment
immunomicelle
immunoparticle
Monoclonal antibodies
Nanoparticles
Payloads
scFv
Therapy
Tumours
Online AccessGet full text

Cover

More Information
Summary:Although combination therapy for cancer utilising monoclonal antibodies in conjunction with chemotherapeutic drugs has resulted in increases in 5 year survivals, there nevertheless remains significant morbidity and mortality associated with systemic delivery of cytotoxic drugs. The advent of living radical polymerisation has resulted in complex and elegant nanoparticle structures that can be engineered to passively target a drug payload for cancer treatment. This presents a therapeutic modality whereby biodistribution and consequently systemic toxicity can be reduced, while focusing drug delivery to the tumour site. Nanoparticle delivery can be enhanced by attachment of a targeting monoclonal antibody fragment to facilitate tumour cell uptake through endocytosis, and so increase therapeutic efficacy. In this way, monoclonal antibodies can be supercharged by carrying a payload consisting of a cocktail of conventional chemotherapeutic drugs and siRNA. This review will focus on antibody‐targeted polymeric nanoparticles to cancer cells, and methods and technologies for synthesising such antibody‐targeted nanoparticles. The review is confined to polymeric‐based nanoparticles as these offer some advantages over liposomal nanoparticles and may circumvent some of the pitfalls in nanomedicine. Development of these antibody based polymeric nanoparticles and future directions for therapy are highlighted in this review. © 2014 Society of Chemical Industry
Bibliography:istex:89928F7C0DBA67EAC3EE6327CFF67B8F1D13E7A8
ark:/67375/WNG-GB784DJ2-7
ArticleID:JCTB4555
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0268-2575
1097-4660
DOI:10.1002/jctb.4555